These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

69 related articles for article (PubMed ID: 26735785)

  • 21. Clinical evaluation of naltrexone treatment of opiate-dependent individuals. Report of the National Research Council Committee on Clinical Evaluation of Narcotic Antagonists.
    Arch Gen Psychiatry; 1978 Mar; 35(3):335-40. PubMed ID: 365122
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of ultra-rapid opiate detoxification on withdrawal syndrome.
    Safari F; Mottaghi K; Malek S; Salimi A
    J Addict Dis; 2010 Oct; 29(4):449-54. PubMed ID: 20924880
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antagonist-precipitated heroin withdrawal under anaesthetic prior to maintenance naltrexone treatment: determinants of withdrawal severity.
    Ali R; Thomas P; White J; McGregor C; Danz C; Gowing L; Stegink A; Athanasos P
    Drug Alcohol Rev; 2003 Dec; 22(4):425-31. PubMed ID: 14660132
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Ultrarapid opiate detoxification: a review.
    Kaye AD; Gevirtz C; Bosscher HA; Duke JB; Frost EA; Richards TA; Fields AM
    Can J Anaesth; 2003; 50(7):663-71. PubMed ID: 12944440
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Drug therapy of opioid withdrawal].
    Cortese S; Risso M
    Vertex; 2008; 19(77):522-6. PubMed ID: 18443666
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Ultra-rapid opioid detoxification: current status and controversies.
    Singh J; Basu D
    J Postgrad Med; 2004; 50(3):227-32. PubMed ID: 15377814
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Opiate addiction in China: current situation and treatments.
    Tang YL; Zhao D; Zhao C; Cubells JF
    Addiction; 2006 May; 101(5):657-65. PubMed ID: 16669899
    [TBL] [Abstract][Full Text] [Related]  

  • 28. In-patient detoxification procedures, treatment retention, and post-treatment opiate use: comparison of lofexidine + naloxone, lofexidine + placebo, and methadone.
    McCambridge J; Gossop M; Beswick T; Best D; Bearn J; Rees S; Strang J
    Drug Alcohol Depend; 2007 Apr; 88(1):91-5. PubMed ID: 17064857
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Ultra-rapid opiate detoxification using dexmedetomidine under general anesthesia.
    Nasr DA; Omran HA; Hakim SM; Mansour WA
    J Opioid Manag; 2011; 7(5):337-44. PubMed ID: 22165032
    [TBL] [Abstract][Full Text] [Related]  

  • 30. New insights and treatments: opiate withdrawal and cocaine addiction.
    Gold MS; Dackis CA
    Clin Ther; 1984; 7(1):6-21. PubMed ID: 6394130
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Neurochemical basis of ultra rapid opioid detoxication].
    Golovko AI; Leont'eva LV; Golovko SI; Zefirov SIu; Konoplin DA; Romanenko OP
    Vopr Med Khim; 2002; 48(2):154-73. PubMed ID: 12189623
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Management of opiate detoxification in jails.
    Fiscella K; Moore A; Engerman J; Meldrum S
    J Addict Dis; 2005; 24(1):61-71. PubMed ID: 15774411
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Long-term methadone maintenance reduces protracted symptoms of heroin abstinence and cue-induced craving in Chinese heroin abusers.
    Shi J; Zhao LY; Epstein DH; Zhang XL; Lu L
    Pharmacol Biochem Behav; 2007 May; 87(1):141-5. PubMed ID: 17532034
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Acute opioid physical dependence in humans: effect of varying the morphine-naloxone interval. I.
    Heishman SJ; Stitzer ML; Bigelow GE; Liebson IA
    J Pharmacol Exp Ther; 1989 Aug; 250(2):485-91. PubMed ID: 2760839
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Total neurochemical lesion of noradrenergic neurons of the locus ceruleus does not alter either naloxone-precipitated or spontaneous opiate withdrawal nor does it influence ability of clonidine to reverse opiate withdrawal.
    Caillé S; Espejo EF; Reneric JP; Cador M; Koob GF; Stinus L
    J Pharmacol Exp Ther; 1999 Aug; 290(2):881-92. PubMed ID: 10411605
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Buprenorphine's physical dependence potential: antagonist-precipitated withdrawal in humans.
    Eissenberg T; Greenwald MK; Johnson RE; Liebson IA; Bigelow GE; Stitzer ML
    J Pharmacol Exp Ther; 1996 Feb; 276(2):449-59. PubMed ID: 8632309
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A new approach to preventing relapse in opiate addicts: a psychometric evaluation.
    Grüsser SM; Thalemann CN; Platz W; Gölz J; Partecke G
    Biol Psychol; 2006 Mar; 71(3):231-5. PubMed ID: 16046046
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Long-term relapse of ultra-rapid opioid detoxification.
    Salimi A; Safari F; Mohajerani SA; Hashemian M; Kolahi AA; Mottaghi K
    J Addict Dis; 2014; 33(1):33-40. PubMed ID: 24471478
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Opioid detoxification and naltrexone induction strategies: recommendations for clinical practice.
    Sigmon SC; Bisaga A; Nunes EV; O'Connor PG; Kosten T; Woody G
    Am J Drug Alcohol Abuse; 2012 May; 38(3):187-99. PubMed ID: 22404717
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Opioid antagonists under heavy sedation or anaesthesia for opioid withdrawal.
    Gowing L; Ali R; White JM
    Cochrane Database Syst Rev; 2010 Jan; 2010(1):CD002022. PubMed ID: 20091529
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.